OncoMyx Announces Three Presentations of New Data for a Novel Oncolytic Immunotherapy of a Multi-Armed Myxoma Virus at AACR Virtual Annual Meeting I

< back

PHOENIX, March 19, 2021 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced the planned presentation of three posters at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021. Two posters (1920 and 1921) will describe preclinical studies of oncolytic activity, transgene production, immunomodulatory mechanisms of action, and efficacy of intratumoral (IT) and intravenous (IV) administration of OncoMyx’s multi-armed myxoma virotherapy for the treatment of cancer. A third poster (1919) in collaboration with Applied Biomath will present data on pharmacological modeling of predicted systemic cytokine exposure after IV administration of myxoma virotherapy.

The posters will be available for viewing in the virtual poster hall on Saturday, April 10, starting at 8:30 am ET. Details of the presentations are as follows:

  • (1919) Prediction of systemic cytokine exposure in human after IV administration of oncolytic myxoma virus, using quantitative systems pharmacology modeling
  • (1920) Armed oncolytic myxoma virus demonstrates transgene production, function, and therapeutic activity xenograft models
  • (1921) Armed oncolytic myxoma virus demonstrates efficacy in syngeneic tumor models alone and in combination with immune checkpoint inhibitors

Titles and/or full abstracts are available on the AACR Virtual Annual Meeting website. Posters for both presentations will be available on OncoMyx’s website on April 10th.

About Oncolytic Immunotherapy and Myxoma Virus

Oncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well to treatment with immune checkpoint inhibitors. Myxoma virus (MYXV) is a member of the Pox family of double stranded DNA viruses. The natural host of MYXV is a subset of rabbits and hares, but MYXV is able to infect cancer cell lines of humans and other species. The genome of MYXV is relatively large and is amenable to engineering for expression of transgenic proteins, making it an excellent oncolytic virus for introduction of immunomodulatory proteins.

About OncoMyx Therapeutics

OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have the potential to be a safe and effective complement to immunotherapies. The company’s MYXV platform, exclusively licensed from Arizona State University, is poised to be a best-in-class OV approach, and the top OV team has assembled around MYXV to create important new therapeutic options for cancer patients.

Corporate Contact: Michael G. Wood, Cofounder, COO, and CFO, mw@oncomyx.com

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com , +1.858.344.8091